



May 13, 2026

Company name: PHC HOLDINGS CORPORATION
 Representative: Kyoko Deguchi,
 President, Representative Director and CEO
 Securities code: 6523 (Tokyo Stock Exchange PRIME Market)
 Contact: Masashi Kimura,
 Executive General Manager of
 Corporate Administration Department
 (TEL: +81-3-5408-7280)

Notice Regarding Differences between Consolidated Full-Year Financial Forecasts and Actual Results

PHC Holdings Corporation (hereinafter referred to as "the Company") hereby announces differences between the consolidated full-year financial forecasts for the fiscal year ended March 31, 2026 (April 1, 2025 through March 31, 2026), which was announced on February 12, 2026, and the actual results disclosed today, as described below.

1. Differences between the consolidated full-year financial forecasts and the actual results for the fiscal year ended March 31, 2026 (April 1, 2025 through March 31, 2026)

	Revenue (Million JPY)	Operating profit (Million JPY)	Profit before tax (Million JPY)	Profit (Million JPY)	Profit attributable to owners of parent (Million JPY)	Basic earnings per share attributable to owners of parent (JPY)	*Adjusted EBITDA (Million JPY)
Previously announced forecasts (A)	363,100	20,000	4,400	2,000	2,000	15.82	47,800
Actual results (B)	364,403	22,688	6,390	219	492	3.90	51,959
Change (B - A)	1,303	2,688	1,990	(1,781)	(1,508)	(11.92)	4,159
Change (%)	0.4	13.4	45.2	(89.1)	(75.4)	(75.3)	8.7
(Reference) Actual consolidated results for the previous fiscal year (Fiscal year ended March 31, 2025)	361,593	22,580	18,823	10,364	10,485	83.13	50,095

(Note) Adjusted EBITDA is calculated with the following formula:

Adjusted EBITDA = EBITDA + one-time income and expenses

EBITDA = Operating profit + depreciation + impairment loss (excluding marketable securities)

* Adjusted EBITDA is not a measure in accordance with IFRS. However, the Company believes that this disclosure may be useful information to investors.

2. Reason for the differences

Operating profit exceeded the previously announced forecast by approximately JPY 2.7 billion, as the decline in Healthcare Solutions was offset by strong performance in Diabetes Management and cost reductions. As a result, profit before tax exceeded the forecast by approximately JPY 2.0 billion. On the other hand, corporate income tax expense increased by approximately JPY 3.8 billion due to the taxes associated with capital returns from subsidiaries and the recognition of deferred tax liabilities in connection with dividend payments of subsidiaries, etc. As a result, profit for the fiscal year amounted to approximately JPY 200 million, and profit attributable to owners of the parent amounted to approximately JPY 500 million.

Please note that the year-end dividend of JPY 21 will remain unchanged since the financial results have exceeded the forecasts.